Loading...

MIRA MIRA PHARMACEUTICALS INC Company Mergers 8-K Filing

MR P

MR

MIRA PHARMACEUTICALS INC

(MIRA)

2025 8-K

Show Summary

Show Summary

Asset Acquisitions

Clinical Trials

Product Expansion

Positive Study Results

Clinical Trial Launch

Acquisition Agreement

Product Development

Clinical Trial Approval

Accounting Firm Change

Drug Safety Validation

Management Changes

Clinical Trial Announcement

Ketamir-2 Efficacy

Ketamine Study Results

Annual Meeting Results

Drug Development Update

Preclinical Success

Compliance Regained

Preclinical Study Data on K...

Preclinical Success

Delisting Notice

Changes in Management

Board Restructuring and Res...

Discovery of New Molecule

Resignation of Director

Appointment and Resignation

License Agreement and Loan ...

Appointment and Resignation...

Amendment to Employment Agr...

Public Offering

External Links:

On March 19, 2025, MIRA Pharmaceuticals, Inc. signed a letter of intent to acquire SKNY Pharmaceuticals, which includes a $5 million cash infusion and aims to enhance MIRA's drug development pipeline with SKNY-1, a drug candidate for weight loss and

AI Assistant

MIRA PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.